Atherosclerosis Drugs Market Expected to Reach $27.7 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Atherosclerosis Drugs Market," The atherosclerosis drugs market size was valued at $20.6 billion in 2022, and is estimated to reach $27.7 billion by 2032, growing at a CAGR of 3% from 2023 to 2032. The atherosclerosis drugs market analysis from 2022 to 2032 to identify the prevailing atherosclerosis drugs market opportunity.  

Upsurge in number of patients suffering from cardiovascular diseases acts as the key driver of the global atherosclerosis drugs market share. Factors such as unhealthy diet, sedentary lifestyle, and tobacco use contribute to the growth in incidence of atherosclerosis. For instance, according to 2021 report by the National Library of Medicines, high 10-year atherosclerotic cardiovascular disease (ASCVD) risk was found in 32% men and 7.6% women, whereas lifetime risk was present in 67% and 51%, respectively. Thus, rise in cases of cardiovascular disease led to increase in demand for atherosclerosis drugs.  In addition, rise in elderly population is a major driver of the atherosclerosis drugs market growth as the geriatric population is highly susceptible to atherosclerotic cardiovascular diseases.    

Moreover, surge in prevalence of cardiac diseases due to sedentary lifestyle and increase in awareness regarding routine testing and management of healthy lifestyle are expected to boost the growth of market during atherosclerosis drugs market forecast period. However, side effects of atherosclerosis drugs such as fatigue, dizziness, and headache hamper the growth of the market during the forecast period. Conversely, upsurge in number of gym and fitness club are expected to provide numerous opportunities for market growth during the forecast period.    

The COVID-19 pandemic negatively impacted the atherosclerosis drugs market as investments in R&D of novel atherosclerosis drugs that target atherosclerosis as well as funding by various companies engaged in the R&D sector were postponed during the pandemic. Moreover, delayed clinical trials of atherosclerosis drugs hindered the growth of the global atherosclerosis drugs market size.  

The global atherosclerosis drugs market is segmented into drug type, route of administration, distribution channel, and region. By drug type, the anti-platelet and anticoagulant segment dominated the atherosclerosis drugs market share in 2022, owing to increase in prevalence of atherosclerotic cardiovascular, which fueled the demand for antiplatelet drugs.  

Depending on route of administration, the oral segment dominated market in 2022 and is expected to remain dominant during the forecast period, owing to rise in preference for oral administration of drugs, as they are cost-effective. On the other hand, the injectable segment is projected to exhibit the fastest market growth during the forecast period, owing to the fact that injectable route provides benefits such as rapid onset of action, high bioavailability, greater precision, and high efficacy.

Moreover, commercialization of novel drugs and increase in product approval of atherosclerosis drugs propel the growth of atherosclerosis drugs market share. Furthermore, the presence of a plethora of products in the pipeline and high growth potential in untapped emerging economies are anticipated to serve as attractive opportunities for market growth during the forecast period. Moreover, surge in medical tourism in developing economies and rapid implementation of technology in healthcare industry significantly propel the growth of the market.   

On the basis of distribution channel, the drug stores & retail pharmacies segment dominated the atherosclerosis drugs industry in 2022 and is expected to remain dominant during the forecast period, owing to ease of accessibility of retail pharmacies and large chain of distribution networks. However, the online providers segment exhibited the fastest CAGR growth during the forecast period. This is attributed to availability of atherosclerosis drugs such as ACE inhibitors and antiplatelet medications on e-commerce platforms which helps patients buy products at ease and increased access to information offered by online providers, which make them an attractive option for patients with atherosclerosis who require medications for their treatment.   

Region wise, North America dominated the atherosclerosis drugs industry in 2022 due to presence of large patient population, strong presence of key players, ease of product availability, and well-developed healthcare infrastructure. In addition, favorable reimbursement policies and higher health awareness about early diagnosis and treatment boost the market growth.    

However, Asia-Pacific is projected to register the highest CAGR during the forecast period. The evolving healthcare regulatory landscape and the government's emphasis on enhancing R&D capabilities for innovative product development are the key factors that boost the growth of the atherosclerosis drugs market trends in the region.

According to Onkar Sumant, Manager, Healthcare at Allied Market Research, “growth of the atherosclerosis drugs market is driven by increase in demand for atherosclerosis drugs due to rise in prevalence of atherosclerosis and rise in geriatric population.” 

Key Findings of The Study 

• By drug type, the antiplatelet and anticoagulant segment held largest share in the global market in 2022.  

• By route of administration, the oral segment dominated the market in 2022. 

• By distribution channel, the drug stores & retail pharmacies segment dominated the market in 2022. 

• Region wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.